Allogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Sells $10,950.84 in Stock

Allogene Therapeutics, Inc. (NASDAQ:ALLO) SVP Earl Martin Douglas sold 6,404 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $1.71, for a total value of $10,950.84. Following the transaction, the senior vice president now directly owns 587,848 shares of the company’s stock, valued at approximately $1,005,220.08. This represents a 1.08 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Allogene Therapeutics Stock Up 1.2 %

Allogene Therapeutics stock traded up $0.02 during trading hours on Wednesday, reaching $1.64. 2,197,203 shares of the company’s stock were exchanged, compared to its average volume of 2,824,648. The firm’s 50 day simple moving average is $2.06 and its 200 day simple moving average is $2.45. Allogene Therapeutics, Inc. has a twelve month low of $1.61 and a twelve month high of $5.78. The firm has a market capitalization of $343.86 million, a PE ratio of -1.05 and a beta of 0.83.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on ALLO shares. William Blair reaffirmed an “outperform” rating on shares of Allogene Therapeutics in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of Allogene Therapeutics in a research report on Friday, November 8th. Finally, Piper Sandler lowered their target price on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.73.

Institutional Trading of Allogene Therapeutics

Several large investors have recently made changes to their positions in ALLO. Private Advisor Group LLC acquired a new stake in shares of Allogene Therapeutics in the 3rd quarter valued at about $34,000. Algert Global LLC acquired a new stake in shares of Allogene Therapeutics in the 2nd quarter valued at about $35,000. MML Investors Services LLC acquired a new stake in shares of Allogene Therapeutics in the 3rd quarter valued at about $56,000. AQR Capital Management LLC acquired a new stake in shares of Allogene Therapeutics in the 2nd quarter valued at about $64,000. Finally, EP Wealth Advisors LLC grew its stake in shares of Allogene Therapeutics by 125.6% in the 3rd quarter. EP Wealth Advisors LLC now owns 24,475 shares of the company’s stock valued at $69,000 after buying an additional 13,625 shares during the period. 83.63% of the stock is currently owned by institutional investors and hedge funds.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).